全球转甲状腺素蛋白淀粉样心肌病治疗市场 - 行业趋势和 2029 年预测

市场分析和洞察全球转甲状腺素蛋白淀粉样心肌病治疗市场

预计在 2022 年至 2029 年的预测期内，转甲状腺素蛋白淀粉样心肌病治疗市场将以 25.1% 的速度增长，到 2029 年预计将达到 292.832 亿美元的价值。Data Bridge Market Research 关于转甲状腺素蛋白淀粉样心肌病治疗市场的报告提供了有关预计在整个预测期内普遍存在的各种因素的分析和见解，同时提供了它们对市场增长的影响。全球医疗保健行业的崛起正在加速转甲状腺素蛋白淀粉样心肌病治疗市场的增长。

转甲状腺素蛋白淀粉样变性心肌病 (ATTR-CM) 是指一种会影响心脏的转甲状腺素蛋白淀粉样变性 (ATTR)。这种疾病会导致限制性心肌病和进行性心力衰竭。这种疾病是一种罕见、诊断不足且危及生命的疾病，会对心脏肌肉造成损害。

The surge in the number of people suffering from transthyretin amyloid cardiomyopathy across the globe acts as one of the major factors driving the growth of transthyretin amyloid cardiomyopathy treatment market. The increase in demand for specific drugs for treating symptoms of the rare disorder and improvement in diagnostic procedures for better diagnosis accelerate the market growth. The increase in in number of clinical trials for enhancement of drugs and therapies, and high focus on research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) treatment further influence the market. Additionally, rise in healthcare expenditure, research and development activities, growth in awareness and improvement of healthcare services positively affect the transthyretin amyloid cardiomyopathy treatment market. Furthermore, development of a novel drug products extend profitable opportunities to the market players in the forecast period of 2022 to 2029.

On the other hand, high cost associated with the treatment and lack of diagnosis are expected to obstruct the market growth. Lack of skilled professionals is projected to challenge the transthyretin amyloid cardiomyopathy treatment market in the forecast period of 2022-2029.

This transthyretin amyloid cardiomyopathy treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info transthyretin amyloid cardiomyopathy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Transthyretin Amyloid Cardiomyopathy Treatment Market Scope and Market Size

The transthyretin amyloid cardiomyopathy treatment market is segmented on the basis of drug, indication, distribution channel and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of product type, the transthyretin amyloid cardiomyopathy treatment market is segmented into inostersen, nonsteroidal anti-inflammatory drugs (NSAID), partisiran, tafamidis and others.
• On the basis of Indication, the transthyretin amyloid cardiomyopathy treatment market is segmented into wild type ATTR amyloidosis and hereditary ATTR amyloidosis.
• On the basis of distribution channel, the transthyretin amyloid cardiomyopathy treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
• On the basis of end-users, the transthyretin amyloid cardiomyopathy treatment market is segmented into hospitals, homecare, specialty clinics and others.

Transthyretin Amyloid Cardiomyopathy Treatment Market Country Level Analysis

The transthyretin amyloid cardiomyopathy treatment market is analyzed and market size information is provided by country, drug, indication, distribution channel and end-users as referenced above.

The countries covered in the global transthyretin amyloid cardiomyopathy treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the transthyretin amyloid cardiomyopathy treatment market due to the increase in the number of diagnosis procedures and presence of leading manufacturers within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the expansion of the pharmaceutical industry in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The transthyretin amyloid cardiomyopathy treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Transthyretin Amyloid Cardiomyopathy Treatment Market Share Analysis

转甲状腺素蛋白淀粉样心肌病治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司关注的转甲状腺素蛋白淀粉样心肌病治疗市场有关。

转甲状腺素蛋白淀粉样心肌病治疗市场的一些主要参与者包括默克公司、辉瑞公司、阿斯利康、Prothena Corporation plc.、Ionis Pharmaceuticals、BELLUS Health Inc.、Alnylam Pharmaceuticals, Inc.、Prothena、葛兰素史克公司、Eidos Therapeutics 和 SOM BIOTECH 等。

SKU-67511